Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
Targeting the inactive state: A new chapter in PI3Kδ inhibition
Industry Insight
The biology of roginolisib: Activity without immune toxicity
Industry Insight
End of year reflections from our CEO
Industry Insight
Driving breakthroughs for myelofibrosis care
Industry Insight
What’s next for cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura expands roginolisib trials to the US
Industry Insight
iOnctura enhances board to accelerate growth and innovation
Industry Insight
Addressing drug resistance in non-small cell lung cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All news
Data & publication
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
Data & publication
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion
Data & publication
Roginolisib stabilizes inactive PI3Kδ to deliver specific target blockade with reduced immune toxicity
Data & publication
A renaissance in targeting the PI3K/AKT/mTOR pathway
Data & publication
IOA-244, a novel p110δ PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy
Data & publication
The PULMO-01 phase I/IIa Study of Roginolisib in combination with dostarlimab, with or without docetaxel, in patients with advanced non-squamous NSCLC who have progressed on standard of care therapy
Data & publication
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity
Press release
iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference
Press coverage
Drug Discovery World – Autotaxin inhibition: unlocking new frontiers in cancers and beyond
Data & publication
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Data & publication
The selective PI3Kδ inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAKi-refractory/resistant patients with myelofibrosis
Data & publication
Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)
Looking for media
resources?